Paul Howard and Luke Timmerman discuss the decline in early stage financing for start-up biotech companies, implications for the pharmaceutical industry, and the future of innovation in life sciences
Paul Howard and Luke Timmerman, discuss the decline in early stage venture capital financing for start-up biotech companies, implications for the pharmaceutical industry, and the future of innovation in the life sciences.